Genmab — Maj 2017
-
de har nu ikke mange mAb'er på vej... http://www.gilead.com/research/pipeline
-
med den brede portefølje GILD har i deres pipeline, kan vi vel næsten kun gå ud fra at de er ivrige efter at fylde noget kød på den
-
-
Ofatumumab not completely forgotten, in new combo trial NCT03136146 acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL). https://clinicaltrials.gov/ct2/show/NCT03136146?term=Ofatumumab&recr=Open&rcv_s=04%2F20
%2F2017&rank=1 -
lets try that link again... https://clinicaltrials.gov/ct2/show/NCT03136146?t
erm=Ofatumumab&recr=Open&rcv_s=04%2F20%2F2017&rank=1 -
præcis samme historie som i går
-
-
Lyder flot Darvin. Men Teprotumumab kan vist ikke nå ret mange patienter. Og derfor ingen interesse fra Big Pharma!
-
Ville blot dele linket. Lige nu er det kun positivt for Genmab at det udvikler sig godt. Mht Graves Disease så rammer den ca 10 millioner amerikanere og tilsvarende andel andre steder. Nu husker jeg ikke andelen, men omkring halvdelen får øjenproblenet og det rammer primært kvinder. Og ....?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind